Condition: MDS · AML · Sponsor: GWT-TUD GmbH
To compare the event-free survival at 2 years of CPX-351 vs. conventional care regimens before allogeneic blood cell transplantation as first line treatment in patients with higher risk MDS and oligoblastic AML.
This description comes directly from the study's public registry record.
Arnold Schröder, Dr. · +49 (0) 351 25933 · arnold.schroeder@g-wt.de
Always discuss trial participation with your own doctor first.
| Ordensklinikum Linz Elisabethinen GmbH | Linz, Austria | Recruiting |
| Uniklinikum Salzburg - Landeskrankenhaus | Salzburg, Austria | Withdrawn |
| Universitätsklinikum Aachen | Aachen, Germany | Recruiting |
| Universitätsklinikum Augsburg | Augsburg, Germany | Recruiting |
| Charité - Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
| Helios Klinikum Berlin-Buch GmbH | Berlin, Germany | Recruiting |
| Universitätsklinikum Bonn (UKB) | Bonn, Germany | Recruiting |
| Klinikum Chemnitz-gGmbH | Chemnitz, Germany | Recruiting |
| Universitätsklinikum Köln | Cologne, Germany | Recruiting |
| Universitätsklinikum Carl Gustav Carus Dresden | Dresden, Germany | Recruiting |
| Universitätsklinikum Düsseldorf | Düsseldorf, Germany | Recruiting |
| Universitätsklinikum Essen | Essen, Germany | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04061239